Rare Diseases
News from NORD
Organic Acidemia Association Launches Natural History Study With NORD
News from NORD
Wyck Foundation and Myotonic Dystrophy Foundation Offer Training Fellowships
News from NORD
Immune Deficiency Foundation Seeks to Connect With Those Diagnosed With WHIM Syndrome
News from NORD
DUP15q Alliance to Host Scientific Symposium and Family Conference
News from NORD
Cutaneous Lymphoma Foundation Conference to Take Place June 24-25
News from NORD
Children’s Cardiomyopathy Foundation Announces Research Funding Availability
News from NORD
NIH Workshop Focuses on Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
News from NORD
NORD Rare Action Network Issues Spring 2017 State Policy Legislative Tracker
News from NORD
NORD Issues RFPs for 2017 Research Grants for Study of Rare Diseases
News from NORD
Patient Advocacy Groups Oppose AHCA
Conference Coverage
PATH study: Subcutaneous immunoglobulin safe, effective for CIDP maintenance
BOSTON – No differences in relapse recurrence were noted between low and high doses in the randomized, placebo-controlled, phase III study.